| Project/Area Number |
15590783
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
KUMAGAI Koichiro Fukuoka University, School of Medicine, Associate Professor, 医学部, 講師 (10248510)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SEGAWA Namiko Fukuoka University, School of Medicine, Assistant Professor, 医学部, 助手 (80352251)
SAKU Keijiro Fukuoka University, School of Medicine, Professor, 医学部, 教授 (40183371)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2005: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2004: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | arrhythmia / atrial fibrillation / inflammation / statins |
|---|
| Research Abstract |
Objective : It has been recently reported that AF is associated with tissue inflammation. Statins reduce C-reactive protein(CRP)levels. However, the effect of statin on atrial fibrillation (AF) is unclear. The purpose of the present study was to evaluate the effect of statin on AF in a canine sterile pericarditis model. Methods : Sterile pericarditis was created in 20 dogs randomly assigned to two groups : a control group (10 dogs) and an atorvastatin treatment group (10 dogs). Atorvastatin was administered orally (2 mg/kg/day) beginning 1 week before the operation until the end of the study. Before and 2 days after the operation, CRP levels, the duration of induced AF, the atrial effective refractory period (AERP), and intra-atrial conduction time were determined. Results : Before the operation, there were no significant differences in any of the parameters between the 2 groups. On the 2nd postoperative day, the atorvastatin group had a lower CRP level (7.6±0.5 versus 11.7±1.3 mg/dL, P<0.0001), a shorter AF duration (177±57 versus 534±189 sec, P<0.0001), a longer AERP (138±6 versus 130±6 ms, P<0.01), and a shorter intra-atrial conduction time (46±3 versus 51±5 ms, P<0.01) than the control group. Conclusions : Atorvastatin can prevent maintenance of AF by inhibiting inflammation in the canine sterile pericarditis model. Atorvastatin may thus be a novel therapeutic agent for AF.
|
